These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 10639365)

  • 1. Toxicity of LY303366, an echinocandin antifungal, in mice pretreated with glucocorticoids.
    Clemons KV; Sobel RA; Stevens DA
    Antimicrob Agents Chemother; 2000 Feb; 44(2):378-81. PubMed ID: 10639365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits.
    Petraitis V; Petraitiene R; Groll AH; Bell A; Callender DP; Sein T; Schaufele RL; McMillian CL; Bacher J; Walsh TJ
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2898-905. PubMed ID: 9797223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis.
    Verweij PE; Oakley KL; Morrissey J; Morrissey G; Denning DW
    Antimicrob Agents Chemother; 1998 Apr; 42(4):873-8. PubMed ID: 9559799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents.
    Pfaller MA; Messer SA; Coffman S
    Antimicrob Agents Chemother; 1997 Apr; 41(4):763-6. PubMed ID: 9087485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp.
    Marco F; Pfaller MA; Messer SA; Jones RN
    Diagn Microbiol Infect Dis; 1998 Sep; 32(1):33-7. PubMed ID: 9791755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LY303366 exhibits rapid and potent fungicidal activity in flow cytometric assays of yeast viability.
    Green LJ; Marder P; Mann LL; Chio LC; Current WL
    Antimicrob Agents Chemother; 1999 Apr; 43(4):830-5. PubMed ID: 10103187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp.
    Serrano Mdel C; Valverde-Conde A; Chávez M M; Bernal S; Claro RM; Pemán J; Ramirez M; Martín-Mazuelos E
    Diagn Microbiol Infect Dis; 2003 Feb; 45(2):131-5. PubMed ID: 12614985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.
    Petraitis V; Petraitiene R; Groll AH; Sein T; Schaufele RL; Lyman CA; Francesconi A; Bacher J; Piscitelli SC; Walsh TJ
    Antimicrob Agents Chemother; 2001 Feb; 45(2):471-9. PubMed ID: 11158743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits.
    Petraitiene R; Petraitis V; Groll AH; Candelario M; Sein T; Bell A; Lyman CA; McMillian CL; Bacher J; Walsh TJ
    Antimicrob Agents Chemother; 1999 Sep; 43(9):2148-55. PubMed ID: 10471556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibilities of Candida species isolated from the lower gastrointestinal tracts of high-risk patients to the new semisynthetic echinocandin LY303366 and other antifungal agents.
    Zhanel GG; Karlowsky JA; Zelenitsky SA; Turik MA; Hoban DJ
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2446-8. PubMed ID: 9736582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi.
    Pfaller MA; Marco F; Messer SA; Jones RN
    Diagn Microbiol Infect Dis; 1998 Apr; 30(4):251-5. PubMed ID: 9582584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Photoaffinity analog of the semisynthetic echinocandin LY303366: identification of echinocandin targets in Candida albicans.
    Radding JA; Heidler SA; Turner WW
    Antimicrob Agents Chemother; 1998 May; 42(5):1187-94. PubMed ID: 9593148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo.
    Bartlett MS; Current WL; Goheen MP; Boylan CJ; Lee CH; Shaw MM; Queener SF; Smith JW
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1811-6. PubMed ID: 8843286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B.
    Cuenca-Estrella M; Mellado E; Díaz-Guerra TM; Monzón A; Rodríguez-Tudela JL
    J Antimicrob Chemother; 2000 Sep; 46(3):475-7. PubMed ID: 10980178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling.
    Groll AH; Mickiene D; Petraitiene R; Petraitis V; Lyman CA; Bacher JS; Piscitelli SC; Walsh TJ
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2845-55. PubMed ID: 11557479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of endpoints for antifungal susceptibility determinations with LY303366.
    Klepser ME; Ernst EJ; Ernst ME; Messer SA; Pfaller MA
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1387-91. PubMed ID: 9624481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans.
    Ernst EJ; Klepser ME; Pfaller MA
    Antimicrob Agents Chemother; 2000 Apr; 44(4):1108-11. PubMed ID: 10722525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates.
    Uzun O; Kocagöz S; Cetinkaya Y; Arikan S; Unal S
    Antimicrob Agents Chemother; 1997 May; 41(5):1156-7. PubMed ID: 9145888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regional-dependent intestinal absorption and meal composition effects on systemic availability of LY303366, a lipopeptide antifungal agent, in dogs.
    Li C; Fleisher D; Li L; Schwier JR; Sweetana SA; Vasudevan V; Zornes LL; Pao LH; Zhou SY; Stratford RE
    J Pharm Sci; 2001 Jan; 90(1):47-57. PubMed ID: 11064378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in vivo dose-dependent activity of caspofungin and anidulafungin against echinocandin-susceptible and -resistant Aspergillus fumigatus.
    Lewis RE; Liao G; Hou J; Prince RA; Kontoyiannis DP
    J Antimicrob Chemother; 2011 Jun; 66(6):1324-31. PubMed ID: 21486855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.